Anamed gets US nod for intracorneal lens trial:
This article was originally published in Clinica
Anamed has gained the go-ahead from the FDA to begin a clinical trial in the US of its PermaVision intracorneal lens for correcting hyperopia of up to +6 diopters. The Lake Forest, California firm, which CE-marked the product for sale in Europe earlier this year (see Clinica No 969, p 16), plans to start the US trial this autumn. The lenses are made from Anamed's proprietary microporous hydrogel, Nutrapore. They are implanted in a sutureless synthetic keratophakia procedure.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.